|
Heart failure
|
0.600 |
Therapeutic
|
disease |
RGD |
(-)-Epigallocatechin-3-gallate, the major green tea catechin, regulates the desensitization of β1 adrenoceptor via GRK2 in experimental heart failure.
|
29247373 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
(-)-Epigallocatechin-3-gallate, the major green tea catechin, regulates the desensitization of β1 adrenoceptor via GRK2 in experimental heart failure.
|
29247373 |
2018 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Thus, sensitization of the heart failure-promoting AT1 receptor by the RKIP-GRK2 interaction contributes to heart failure whereas dominant-negative GRK2-K220R is cardioprotective.
|
30687708 |
2018 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Since GRK2 has been shown to compromise fatty acid (FA) oxidation, this kinase may link metabolic and contractile defects in HF.
|
30171848 |
2018 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Last, we will update the readers on the current status of GRK2 inhibitors as a potential therapeutic strategy for heart failure with an emphasis on their ability of rescuing NO bioavailability.
|
28077324 |
2018 |
|
Congestive heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The G-protein-coupled receptor kinase 2 (GRK2) plays a major role in cardiovascular diseases, and its expression is increased in heart failure.
|
29905975 |
2018 |
|
Congestive heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Thus, sensitization of the heart failure-promoting AT1 receptor by the RKIP-GRK2 interaction contributes to heart failure whereas dominant-negative GRK2-K220R is cardioprotective.
|
30687708 |
2018 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
In animal models, GRK2 contributes to the pathogenesis of heart failure after ischemia-reperfusion (IR) injury.
|
30538174 |
2018 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
(-)-Epigallocatechin-3-gallate, the major green tea catechin, regulates the desensitization of β1 adrenoceptor via GRK2 in experimental heart failure.
|
29247373 |
2018 |
|
Congestive heart failure
|
0.600 |
Therapeutic
|
disease |
RGD |
(-)-Epigallocatechin-3-gallate, the major green tea catechin, regulates the desensitization of β1 adrenoceptor via GRK2 in experimental heart failure.
|
29247373 |
2018 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Herein, we will update the readers about the 'state-of-art' of GRK2 inhibition as a potent therapeutic strategy in HF.
|
29166798 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure.
|
28699740 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
More consistent to mammalians, adult zebrafish developed significant heart failure in concert with β1-AR downregulation, and GRK2 and brain natriuretic peptide (BNP) upregulation in response to prolonged, 14d ISO-stimulation.
|
28554511 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Small molecule Gβγ-GRK2 inhibition initiated 1 week post-injury was cardioprotective in the I/R model of chronic HF, including preservation of cardiac contractility and a reduction in cardiac fibrotic remodeling.
|
28818206 |
2017 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, chronic overexpression of GRK2 inhibits catecholamine induction of vital positive chronotropic and ionotropic effects required to preserve cardiac output leading to worsening of congestive HF.
|
27222484 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Increased Atrial β-Adrenergic Receptors and GRK-2 Gene Expression Can Play a Fundamental Role in Heart Failure After Repair of Congenital Heart Disease with Cardiopulmonary Bypass.
|
28214967 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
This review summarizes what is currently known regarding the activity of these kinases, and particularly the role of GRK2 and GRK5 in the molecular alterations that occur during heart failure.
|
28328744 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
These studies elucidate a novel mechanism by which hyperinsulinemia contributes to heart failure by increasing PDE4D expression and identify β<sub>2</sub>AR or GRK2 as plausible therapeutic targets for preventing or treating heart failure in subjects with type 2 DM.
|
27815373 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
LVAD treatment in children with heart failure results in reversal of several pathologic myocellular processes, and G protein-coupled receptor kinase-2 may regulate β<sub>1</sub>-AR but not β<sub>2</sub>-adrenergic receptor expression in children with heart failure.
|
27908653 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Via structural and biochemical analyses, the selective serotonin reuptake inhibitor (SSRI) paroxetine was identified as a GRK2 inhibitor that enhances βAR-dependent cardiomyocyte and cardiac contractility and reverses cardiac dysfunction and myocardial βAR expression in mouse models of heart failure.
|
28711716 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The increase in protein activity and upregulation of G-protein coupled receptor kinase 2 (GRK2) is a hallmark of cardiac stress and heart failure.
|
28759639 |
2017 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The increase in protein activity and upregulation of G-protein coupled receptor kinase 2 (GRK2) is a hallmark of cardiac stress and heart failure.
|
28759639 |
2017 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
LVAD treatment in children with heart failure results in reversal of several pathologic myocellular processes, and G protein-coupled receptor kinase-2 may regulate β<sub>1</sub>-AR but not β<sub>2</sub>-adrenergic receptor expression in children with heart failure.
|
27908653 |
2017 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Small molecule Gβγ-GRK2 inhibition initiated 1 week post-injury was cardioprotective in the I/R model of chronic HF, including preservation of cardiac contractility and a reduction in cardiac fibrotic remodeling.
|
28818206 |
2017 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
This review summarizes what is currently known regarding the activity of these kinases, and particularly the role of GRK2 and GRK5 in the molecular alterations that occur during heart failure.
|
28328744 |
2017 |